News
May 11, 2026
BridgeBio Pharma Inc. (BBIO), a commercial-stage biopharmaceutical company, on Monday announced new data from its Phase 3 ATTRibute-CM study of Acoramidis,…
May 11, 2026
Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly recognized yet frequently underdiagnosed cause of heart failure, particularly among older adults.…
May 11, 2026
-Acoramidis increased sTTR early and significantly reduced intra-individual sTTR variability versus placebo (p<0.001), which is associated with reduced ACM,…
May 11, 2026
Bayer has announced successful results from a Phase III clinical trial evaluating its investigational PET tracer, iodine 124 evuzamitide, designed for diagnosing…
May 11, 2026
This weekend at the European Society of Cardiology’s Heart Failure 2026 Congress in Barcelona), the first data from AstraZeneca’s (LSE: AZN) Phase III CARDIO-…
May 11, 2026
People with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) often experience eye-related complications such as eye dryness and floaters in the…
May 11, 2026
The American Heart Association launches cluster randomized trial to improve detection of ATTR cardiomyopathy within hospitals participating in Get With The…
May 11, 2026
TOPLINE:Most older adults with transthyretin cardiac amyloidosis (ATTR-CM) experienced at least 6 months of delay in diagnosis after a first heart failure (HF)…
May 10, 2026
AbstractBackgroundCardiac amyloidosis (CA) is a progressive infiltrative cardiomyopathy associated with conduction disease and arrhythmias, although their true…
May 10, 2026
AbstractBackgroundCardiac amyloidosis is frequently underdiagnosed and rarer forms (e.g., non-transthyretin or light chain amyloidosis) can be challenging to…